Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASC1
- Development stage
- Preclinical
- Lead developer
- Kyungpook National University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ASC1 (Active Single Compound 1) is an experimental therapeutic agent under development by researchers at Kyungpook National University. It is being investigated for the treatment of obesity, type 2 diabetes, and fatty liver disease. In preclinical studies using high-fat diet-induced aging obese mouse models, oral administration of ASC1 (5 mg/kg) significantly reduced body weight gain, liver weight, hepatic triglycerides, and cholesterol levels, while improving glucose metabolism and reducing liver fibrosis. Additionally, ASC1 attenuated hepatic inflammation by suppressing inflammation-related proteins and macrophage activation genes.
- Other names
- Active Single Compound 1
Beyond the preview
Go deeper on ASC1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASC1.